2381089-83-2
Most orderedRetatrutide
Single-molecule agonist at the GIP, GLP-1 and glucagon receptors. Supplied lyophilised and released at ≥ 99.0% by RP-HPLC.
Typical release99.4%
From
£68.00
In stock
Metabolic & Incretin
AOD-9604
hGH fragment 177-191 analogue · AOD9604
Modified C-terminal growth hormone fragment with a tyrosine addition, studied in lipolysis models.
Total, ex VAT
£49.00
- Released at ≥ 98.0% (RP-HPLC, area %)
- Identity confirmed by ESI-MS against theoretical mass
- Batch certificate matched to the vial, verifiable online
- Same working day dispatch before 14:00, tracked
For laboratory research use only. Not for human or veterinary use, and not a medicine, food or cosmetic. Sold to qualified researchers and institutions who accept responsibility for safe handling and lawful use.
Compound data
What is in the vial
Indicative values for this line. The certificate issued with your batch is the authoritative record and reports the measured figures for the material you receive.
- CAS number
- 221231-10-3
- Molecular formula
- C78H123N23O23S2
- Average mass
- 1815.1 g/mol
- Residues
- 16
- Class
- Growth hormone C-terminal fragment analogue
- Form as supplied
- Lyophilised powder
- Appearance
- White to off-white lyophilised powder
- Purity specification
- ≥ 98.0% (RP-HPLC, area %)
- Solubility
- Soluble in sterile or bacteriostatic water.
- Storage
- Lyophilised: −20 °C, desiccated and dark. Reconstituted: 2–8 °C.
Targets and pathways
- Lipolytic pathways downstream of the hGH C-terminal domain
Overview
About AOD-9604
AOD-9604 is the 177-191 C-terminal fragment of human growth hormone with an additional N-terminal tyrosine. The fragment was pursued on the observation that the lipolytic activity of growth hormone is separable from its growth-promoting and glucose-antagonising activity, and that the C-terminal region carries the former.
For research purposes it is used as a dissociation tool: it lets a preparation be exposed to the lipolytic signal without the somatotropic one. The tyrosine addition was introduced to aid radiolabelling and improve stability, and material is supplied with the modification stated on the certificate to avoid confusion with the unmodified fragment.
In short
- hGH(177-191) with an added N-terminal tyrosine
- Separates the lipolytic activity of growth hormone from its growth-promoting activity
- Not interchangeable with unmodified hGH fragment 176-191
- Released at ≥ 98.0% area-percent by RP-HPLC
Where it is used
Research applications
Lipolysis
Used in adipocyte preparations to study fat mobilisation without the confounding glucose effects of full-length growth hormone.
Structure–activity of hGH
The fragment is a working demonstration that hGH's functions are regionally separable within the molecule.
Cartilage and joint models
Reported effects in cartilage preparations have generated a secondary literature separate from the metabolic work.
Handling
Reconstitution and stability
Reconstitution
Reconstitute with sterile or bacteriostatic water added slowly against the inner wall of the vial. Allow the cake to dissolve without agitation, swirling gently if required. Do not vortex or shake.
Stability
Lyophilised at −20 °C, desiccated and protected from light, stable for at least 24 months. Reconstituted and held at 2–8 °C, use within 28 days. Avoid repeated freeze-thaw.
Notes
- Bring the vial to room temperature before opening so atmospheric moisture does not condense onto cold powder.
- Record the reconstitution date on the vial; concentration drift between runs is usually evaporation, not synthesis variance.
- Aliquot at first reconstitution where the working programme needs more than a few withdrawals.
Laboratory reference
Reconstitution calculator
Enter the fill weight on the vial and the diluent volume you intend to add. The calculator returns the resulting solution concentration and the volume that contains a given mass.
- Concentration
- 2.500 mg/mL · 2500 µg/mL
- Volume containing target mass
- 100.0 µL · 0.1000 mL
Figures are mass-to-volume arithmetic for laboratory preparation of AOD-9604 and take no account of net peptide content, which is stated on the batch certificate and should be applied to the fill weight before calculating. Nothing here constitutes dosing, administration or clinical guidance of any kind.
Published work
What the literature reports
Summaries of published findings, provided as research reference. These describe work done by others in preclinical and clinical settings; they are not claims about this material or outcomes for any reader.
Fragment lipolytic activity
Early characterisation showing the C-terminal region of hGH retains lipolytic activity in the absence of the growth-promoting domain.
Ng & Bornstein, Diabetes, 1978
Analogue development
Work describing the tyrosine-modified analogue and its behaviour relative to the parent fragment.
Heffernan et al., Endocrinology, 2001
Questions
AOD-9604 — asked and answered
Something not covered here? Ask us directly — technical questions reach someone who runs the assays.
- Is this the same as HGH fragment 176-191?
- No. AOD-9604 is the 177-191 fragment with an added N-terminal tyrosine. HGH fragment 176-191 is a different, unmodified sequence. They have different masses and are not interchangeable in a method.
- Why the added tyrosine?
- It was introduced to allow radioiodination for tracer studies and improves handling stability. It sits outside the active region.
- What purity is it released at?
- ≥ 98.0% area-percent by RP-HPLC, with identity confirmed by ESI-MS.
Same class
Others in Metabolic & Incretin
910463-68-2
Most orderedSemaglutide
Acylated GLP-1 receptor agonist with a C18 diacid linker. The reference mono-agonist for incretin work.
Typical release99.4%From
£44.00
In stock
2023788-19-2
Most orderedTirzepatide
Dual GIP and GLP-1 receptor agonist. The intermediate step between mono- and tri-agonism.
Typical release99.3%From
£84.00
In stock
Research compound
5-Amino-1MQ
Small-molecule NNMT inhibitor used in methylation and adipocyte metabolism research.
Typical release98.6%From
£56.00
In stock
Important
AOD-9604 is supplied strictly for laboratory research and analytical use. It is not a medicine, food, cosmetic or veterinary product; it is not for human or animal consumption; and it is not intended to diagnose, treat, cure or prevent any condition. It is not manufactured, tested or released to any standard that would support administration to humans or animals. Information on this page is compiled for research reference and is not medical advice. No dosing, administration or therapeutic guidance is given or implied. By ordering you confirm you are a qualified researcher or institution and accept responsibility for safe handling and lawful use.